Ardelyx Posts 73% IBSRELA Revenue Growth, XPHOZAH Dispenses Up 9%
Ardelyx saw IBSRELA revenue jump 73% in 2025 to record Q4 net sales, driven by a specialty pharmacy network that boosted fulfillment rates and contributed to 7 million IBS-C prescriptions, up 11% year over year. XPHOZAH total dispenses rose 9% in 2025 with non-Medicare paid dispenses up 41%.
1. IBSRELA Commercial Momentum
Ardelyx reported 73% revenue growth for IBSRELA in 2025, with the product delivering its highest quarterly net revenue to date. The company expanded its specialty pharmacy network and doubled field reimbursement managers, increasing prescription pull-through and contributing to 7 million IBS-C prescriptions written in 2025, up 11% year over year.
2. XPHOZAH Access Strategy
XPHOZAH posted a 9% increase in total dispenses for the year, driven by access initiatives that raised paid dispenses outside Medicare by 41% despite the loss of Part D reimbursement. The expanded field sales team and patient engagement efforts helped improve fulfillment rates to the highest level since launch.
3. New Patent Extends IP to 2042
Ardelyx secured a new patent covering its commercial formulations of IBSRELA and XPHOZAH, extending intellectual property protection through 2042 via listing in the FDA’s Orange Book. This patent supports the company’s strategy to build a comprehensive IP portfolio around its tenapanor products.
4. Pipeline Progress in CIC and NHE3 Inhibitor
In its pipeline, Ardelyx launched the ACCEL Phase III trial for a chronic idiopathic constipation label expansion of tenapanor, targeting full enrollment of 700 patients by end 2026 and top-line results in the second half of 2027. The company is also advancing a next-generation NHE3 inhibitor with planned IND submission in the second half of 2026.